Incannex filed Form 20-F and XBRL data with SEC
IHL announce that it has filed its Annual Report on Form 20-F containing audited consolidated financial statements for the year… Read more
IHL announce that it has filed its Annual Report on Form 20-F containing audited consolidated financial statements for the year… Read more
KEY HIGHLIGHTS DURING THE QUARTER • 34.5% higher Monthly Recurring Revenue (MRR) in September 2022 ($346K) compared to June 2022,… Read more
Melbourne, Australia, October 28, 2022 – Clinical stage pharmaceutical development company, Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL), (‘Incannex’ or… Read more
Sydney, 27 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in… Read more
Nyrada Inc. released its September quarterly report this morning – ASX release attached. The most significant point which Canary would… Read more
Harvest Technology Group Limited (“the Company”) (ASX: HTG) advise that it has established an unmarketable parcel sale facility (Facility) for… Read more
For the annual general meeting of the Company to be held at the offices of Thomson Geer at Level 27… Read more
Sydney, 18 October 2022: Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in… Read more
HIGHLIGHTS: • 34.5% higher Monthly Recurring Revenue (MRR) in September 2022 ($346K) compared to June 2022, exceeding the forecast minimum… Read more